← Reviews
Open accessFull analysisNov 15, 2026

Vaginal microbiome and cervical antiretroviral exposure: pharmacometric and machine learning analysis

Specific vaginal taxa — not overall microbiome diversity — are associated with variability in cervical exposure to tenofovir, lamivudine, and emtricitabine, with bacterial vaginosis-associated genera showing an unfavorable direction.

Evidence levelCObservational / small clinical study
Study typeobservational
Sample—
Effect directionUnfavorable
CertaintyLow
Clinical applicabilityLow
Overinterpretation risk1/5 · Low
PECO
PopulationWomen receiving tenofovir-, lamivudine-, or emtricitabine-containing regimens
ExposureVaginal microbiome characterization by sequencing + pharmacometric modeling of cervical drug exposure
ComparatorAbsence vs. presence of specific taxa (internal comparisons via nonlinear mixed-effects and machine learning models)
OutcomeCervical tenofovir (TFV) exposure; Cervical lamivudine (3TC) exposure; Cervical emtricitabine (FTC) exposure; Overall microbiome diversity and cervical drug exposure

Summary of findings

OutcomeEffect95% CICertaintyClinical relevanceNotes
Cervical tenofovir (TFV) exposureAssociation with Gemella, Megasphaera, Falsiporphyromonas; effect size not reported—Low—1 studies
Cervical lamivudine (3TC) exposureAssociation with Dialister, Prevotella, Atopobium, Streptobacillus, Gardnerella; effect size not reported—Low—1 studies
Cervical emtricitabine (FTC) exposureAssociation with Bifidobacteriaceae, Lachnospiraceae, Prevotellaceae; effect size not reported—Low—1 studies
Overall microbiome diversity and cervical drug exposureNo significant association; alpha/beta diversity not associated with TFV, 3TC, or FTC cervical exposure—Low—1 studies

Context

Oral PrEP with TDF/FTC is less effective in women than in men who have sex with men, a gap not fully explained by adherence alone. The vaginal microbiome may modulate local antiretroviral pharmacokinetics, potentially compromising HIV protection in women — particularly in sub-Saharan Africa, where incidence in young women is more than three times that of young men.

What the study showed

Overall alpha/beta microbiome diversity was not associated with cervical exposure to any of the three drugs. Specific taxa showed significant associations: Gemella, Megasphaera, and Falsiporphyromonas with TFV; Dialister, Prevotella, Atopobium, Streptobacillus, and Gardnerella with 3TC; Bifidobacteriaceae, Lachnospiraceae, and Prevotellaceae with FTC. Absolute effect sizes (e.g., concentration differences in ng/mL) and individual 95% CIs per taxon were not reported in the available text, limiting precise quantification.

How it was done

Observational study combining nonlinear mixed-effects pharmacometric (PK) modeling with machine learning algorithms to analyze high-dimensional microbiome data alongside cervical antiretroviral concentrations. Sample size (n) and follow-up duration were not specified in the available excerpt. Population: women using TFV, 3TC, or FTC.

Effect magnitude

Effect sizes (RR, OR, SMD, or concentration differences with 95% CI) were not provided in the available text; statistical significance of identified taxa is reported as 'significant' by the authors without accessible numeric values in this excerpt.

Risk of bias

Observational design precludes causal inference between taxa and reduced drug exposure. Sample size, risk-of-bias tool (ROBINS-I would be most applicable), and adjustment for confounders (adherence, menstrual cycle, co-infections) are not detailed in the excerpt. High dimensionality of microbiome data increases overfitting risk in machine learning models; external validation is not mentioned.

Interpretation limit

What this study does NOT prove

This study does not prove that identified taxa cause reduced cervical drug exposure or that microbiome modification improves PrEP efficacy. Results cannot be generalized without validation in populations with different microbiological and epidemiological profiles.

In clinical practice

Evidence is insufficient to change clinical practice based on this single study. Clinicians should note that bacterial vaginosis and taxa such as Gardnerella and Prevotella may be associated with lower cervical antiretroviral exposure, supporting screening and treatment of bacterial vaginosis in PrEP users. Await prospective validation before any microbiome-guided dosing adjustment.

Limitations

Observational design precludes causal inference between taxa and reduced drug exposure. Sample size, risk-of-bias tool (ROBINS-I would be most applicable), and adjustment for confounders (adherence, menstrual cycle, co-infections) are not detailed in the excerpt. High dimensionality of microbiome data increases overfitting risk in machine learning models; external validation is not mentioned.

What is still missing

Prospective studies with direct cervical concentration measurements, quantified effect sizes, and independent validation of machine learning models in distinct cohorts are needed to establish causality and clinical relevance.

Technical appendix

Version history

  • 1.0 · 2026-11-15 — Auto-generated under Evidence Standard v1.0
Source: DOI 10.1002/cpt.70499 · 2026

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.